AZ-23

• Description :

  AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

• Product Name Alternative :

  AZD1332

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Trk Receptor

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/AZ-23.html

• Purity :

  98.92

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  CC(OC1=CC(NC2=NC(N[C@H](C3=NC=C(F)C=C3)C)=NC=C2Cl)=NN1)C

• Molecular Formula :

  C17H19ClFN7O

• Molecular Weight :

  391.83

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Thress K, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8 (7) :1818-27.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  TrkA; TrkB

• CAS Number :

  [915720-21-7]